Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Luis Carlos Vesga has a total of 50 co-authors. Here are the top co-authors by number of shared publications:

  • Stelia Carolina Mendez-Sanchez

    Grupo de Investigación en Bioquímica y Microbiología (GIBIM), Escuela de Química, Universidad Industrial de Santander. Parque tecnológico y de investigaciones, Guatiguará Km 2 Vía El Refugio, 681012, Piedecuesta, Santander, Colombia

    7 shared publications
  • Arnold Rafael Romero Bohorquez

    Grupo de Investigación en Compuestos Orgánicos de Interés Medicinal (CODEIM), Escuela de Química, Universidad Industrial de Santander, Bucaramanga, Colombia

    3 shared publications
  • Jonny Edward Duque

    Centro de Investigaciones en Enfermedades Tropicales—CINTROP, Facultad de Salud, Escuela de Medicina, Departamento de Ciencias Básicas, Universidad Industrial de Santander, Guatiguará Technology and Research Park, Km 2 Vía El Refugio, Piedecuesta 681018, Santander, Colombia

    3 shared publications
  • Antti Poso

    University of Eastern Finland

    2 shared publications
  • Cristian C. Bernal

    Grupo de Investigación en Bioquímica y Microbiología GIBIM, Escuela de Química, Universidad Industrial de Santander, Bucaramanga, Colombia

    2 shared publications
  • Diogo Henrique Kita

    Pharmaceutical Sciences Graduate Program, Laboratory of Cancer Drug Resistance, Federal University of Paraná, Curitiba, PR, Brazil

    2 shared publications

Latest Publications

  • Tetrahydroquinoline/4,5-dihydroisoxazoline hybrids counteracts multidrug resistance by inhibiting MRP1-mediated drug efflux

    by Giovana da Silva Pereira, Luis C. Vesga, Gustavo Scheiffer, Ingrid Fatima Zattoni, Bruna Estelita Ruginsk, Cristian C. Bernal, Arnold R. Romero Bohórquez, Stelia Carolina Mendez-Sanchez, Azam Rashidian, Antti Poso, et al.


  • High-Throughput Screening to Detect Natural Compounds with Pesticidal Properties

    by Luis C. Vesga, Jonathan Lara-Sanchez, Gloria Stefany Avendaño-Mora, Stelia Mendez-Sanchez, Jonny E Duque

    Developing new, biocompatible, and safe pesticides is essential due to the harmful effects of traditional pesticides on human health and the environment. These synthetic chemicals can cause various health issues, from mild irritations to severe conditions like respiratory problems, neuropsychiatric disorders, cancer, and reproductive harm. Consequently, researchers have been focusing on formulating new and efficient biopesticides. Computational approaches have become important tools in identifying new bioactive compounds that target novel and interesting molecular targets such as mitochondrial proteins. Mitochondria are not only the powerhouse of the cell but also play crucial roles in cell death processes and serve as intracellular calcium reservoirs, making them key organelles for pesticide development. The identification of bioactive compounds using computational approaches such as homology modeling, ligand-based screening, structure-based screening, molecular docking, and molecular dynamics simulations can save both time and cost. In this chapter, we show that once lead compounds are identified by following a workflow base on virtual screening, in vitro and in vivo assays can measure their biological activity. Besides, electroantennography is emerging as a vital tool for developing new repellents as an alternative to test these lead compounds. Briefly, combining computational approaches with in vitro, in vivo, and electroantennography assays can provide valuable insights for animal and human health and for controlling pests in the agricultural industry.


  • Unveiling Xenobiotic Transport and Effects in Isolated Mitochondria: Insights from Respirometric and Enzymatic Assays

    by Luis C. Vesga, Jonny E. Duque Luna, Stelia C. Mendez-Sanchez

    Mitochondria are often referred to as the cell's powerhouse due to their crucial role in energy production through the electron transport chain (ETC). However, their significance extends far beyond energy production. Dysregulation of mitochondrial bioenergetics can trigger intracellular cascades that impact health and cellular function. Given their physiological importance, there is growing interest in exploring the pharmacological potential of mitochondrial function for developing new therapies and bioproducts. Modulating mitochondrial bioenergetics could provide innovative approaches to address challenges such as neurodegenerative disorders, metabolic diseases, and cancer, as well as to develop bioproducts for controlling pests and vector-borne diseases. This work presents a method for assessing the effects of xenobiotics on the electron transport chain (ETC) using various substrates, including glutamate and NADH for complex I, succinate for complex II, and cytochrome c (both oxidized and reduced) for complexes III and IV. This methodology allows the activation or inhibition of electron transport through mitochondrial complexes to be evaluated using a respirometer and spectrophotometer. The mitochondria can be sourced from isolated mitochondria, fragmented cells, or homogenized tissue from various species. In the laboratory, mitochondrial function has been analyzed in Aedes aegypti and Wistar rats, but this method is also applicable to other species, such as Rhipicephalus microplus and Rhodnius prolixus. This approach provides the basis for theorizing about the existence of uncoupler proteins and species-specific oxidizable substrate preferences influenced by their unique energetic demands. Recent findings offer valuable insights into innovative bioinsecticide design strategies that target mitochondrial function, holding significant potential for effectively controlling vector-borne diseases and pest infestations.


  • Open Access

    Repurposing of Four Drugs as Anti-SARS-CoV-2 Agents and Their Interactions with Protein Targets

    by Luis C. Vesga, Camilo A. Ruiz-Hernández, Jeimmy J. Alvarez-Jacome, Jonny E. Duque, Bladimiro Rincon-Orozco, Stelia C. Mendez-Sanchez

    Although there are existing vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), new COVID-19 cases are increasing due to low immunization coverage and the emergence of new variants. For this reason, new drugs to treat and prevent severe COVID-19 are needed. Here, we provide four different FDA-approved drugs against SARS-CoV-2 proteins involved in the entry and replication process, aiming to identify potential drugs to treat COVID-19. We use the main protease (Mpro), the spike glycoprotein (S protein), and RNA-dependent RNA polymerase (RdRp) as protein targets for anti- SARS-CoV-2 drugs. In our constructed database, we selected different drugs against each target (Mpro, S protein, and RdRp) based on their common interactions with relevant residues involved in viral entry at the host cell and replication. Furthermore, their stability inside the binding pocket, as well as their predicted binding-free energy, allow us to provide new insight into the possible drug repurposing of viomycin (interacting with Mpro) due to its interactions with key residues, such as Asn 143, Glu 166, and Gln 189 at the same time as hesperidin (interacting with the S protein) is interacting with residues Tyr 449, Ser 494, and Thr 500, keeping inside the predicted binding pocket, as well as interacting with residues in different variants of concern. Finally, we also suggest nystatin and elvitegravir (interacting with RdRp) as possible drugs due to their stability within the predicted pocket along the simulation and their interaction with key residues, such as Asp 760, Asp 761, and Asp 618. Altogether our results provide new knowledge about the possible mechanism of the inhibition of viomycin, hesperidin, elvitegravir, and nystatin to inhibit the viral life cycle of SARS-CoV-2 and some of its variants of concern (VOC). Additionally, some iodide-based contrast agents were also found to bind the S protein strongly, i.e., iohexol (−58.99 Kcal/mol), iotrolan (−76.19 Kcal/mol), and ioxilan (−62.37 Kcal/mol). Despite the information we report here as the possible strong interaction between these contrast agents and the SARS-CoV-2′s S protein, Mpro, and RdRp, we believe that further investigation, including chemical modifications in their structures, are needed for COVID-19 treatment.


  • Cymbopogon flexuosus (nees ex steud.) w. watson essential oil effect on mitochondrial bioenergetics

    by Diana Carolina Montagut, Yenny Bueno, Luis C. Vesga, Elena E. Stashenko, Stelia C. Mendez-Sanchez

    Cymbopogon flexuosus is a medicinal plant with various biological activities. Although its essential oil (EO) is widely used, the effect of C. flexuosus EO on mitochondrial bioenergetics has not been completely elucidated. Here, we report the effect of C. flexuosus EO on electron transport through the mitochondrial respiratory chain using isolated mitochondria from liver rats. The EO decreases the oxygen consumption rate up to −20% at 10 ppm, and −17% at 25 ppm using glutamate and succinate, respectively. The C. flexuosus EO inhibits the NADH oxidase (34%), succinate oxidase (53%), succinate dehydrogenase (44%), and cytochrome c oxidase (69%) activities at 10 ppm, which indicates a robust inhibitory effect on the electron transport chain. Our results show the inhibitory effect of C. flexuosus EO on electron transport through complex II and IV and suggest that this EO could be used as a potential drug to treat mitochondrial diseases, including cancer.


  • A new porphyrin as selective substrate-based inhibitor of breast cancer resistance protein (BCRP/ABCG2)

    by Ingrid Fatima Zattoni, Thales Kronenberger, Diogo Henrique Kita, Lais Danciguer Guanaes, Matheus Murmel Guimarães, Larissa de Oliveira Prado, Melanie Ziasch, Luis C. Vesga, Fabiane Gomes de Moraes Rego, Geraldo Picheth, et al.


  • Tetrahydroquinoline/4,5-dihydroisoxazole hybrids with a remarkable effect over mitochondrial bioenergetic metabolism on melanoma cell line B16F10

    by Luis C. Vesga, Ana Milena Pérez Silva, Cristian C. Bernal, Stelia Carolina Mendez-Sánchez, Arnold R. Romero Bohórquez

  • Spatial control of gene expression in flies using bacterially derived binary transactivation systems

    by S. Gamez, L. C. Vesga, S. C. Mendez‐Sanchez, O. S. Akbari

    Controlling gene expression is an instrumental tool for biotechnology, as it enables the dissection of gene function, affording precise spatial–temporal resolution. To generate this control, binary transactivational systems have been used employing a modular activator consisting of a DNA binding domain(s) fused to activation domain(s). For fly genetics, many binary transactivational systems have been exploited in vivo ; however, as the study of complex problems often requires multiple systems that can be used in parallel, there is a need to identify additional bipartite genetic systems. To expand this molecular genetic toolbox, we tested multiple bacterially derived binary transactivational systems in Drosophila melanogaster including the p ‐CymR operon from Pseudomonas putida , PipR operon from Streptomyces coelicolor , TtgR operon from Pseudomonas putida and the VanR operon from Caulobacter crescentus . Our work provides the first characterization of these systems in an animal model in vivo . For each system, we demonstrate robust tissue‐specific spatial transactivation of reporter gene expression, enabling future studies to exploit these transactivational systems for molecular genetic studies.


  • Open Access

    Tetrahydroquinoline/4,5‐Dihydroisoxazole Molecular Hybrids as Inhibitors of Breast Cancer Resistance Protein (BCRP/ABCG2)

    by Luis C. Vesga, Thales Kronenberger, Arun Kumar Tonduru, Diogo Henrique Kita, Ingrid Fatima Zattoni, Cristian Camilo Bernal, Arnold R. Romero Bohórquez, Stelia Carolina Mendez‐Sánchez, Suresh V. Ambudkar, Glaucio Valdameri, et al.

    Multidrug resistance (MDR) is one of the major factors in the failure of many chemotherapy approaches. In cancer cells, MDR is mainly associated with the expression of ABC transporters such as P‐glycoprotein, MRP1 and ABCG2. Despite major efforts to develop new selective and potent inhibitors of ABC drug transporters, no ABCG2‐specific inhibitors for clinical use are yet available. Here, we report the evaluation of sixteen tetrahydroquinoline/4,5‐dihydroisoxazole derivatives as a new class of ABCG2 inhibitors. The affinity of the five best inhibitors was further investigated by the vanadate‐sensitive ATPase assay. Molecular modelling data, proposing a potential binding mode, suggest that they can inhibit the ABCG2 activity by binding on site S1, previously reported as inhibitors binding region, as well targeting site S2, a selective region for substrates, and by specifically interacting with residues Asn436, Gln398, and Leu555. Altogether, this study provided new insights into THQ/4,5‐dihydroisoxazole molecular hybrids, generating great potential for the development of novel most potent ABCG2 inhibitors.


  • Synthesis and anticancer activity of new tetrahydroquinoline hybrid derivatives tethered to isoxazoline moiety

    by Cristian C. Bernal, Luis C. Vesga, Stelia Carolina Mendez-Sánchez, Arnold R. Romero Bohórquez